An increase in CD4+ T-lymphocyte content and CD4+/CD8+ ratio means that the tumor is still in an early clinical stage, while an increase in CD8+ T-lymphocyte content means that the tumor has escalated to an advanced stage. This evidence concerns the gene CD4 and neoplasm.